Skip to content
DataLookout
Menu

NCT04294628

Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 87 versions: 12 with changes below, 38 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 17, 2026 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: 3 to 5
    • Study description expanded, about 28 words
    • Site details revised at 1 of 6 sites
  2. Notable Primary endpoints revised (2)
    • Secondary endpoints revised (3)
    v84
  3. Minor Enrollment target: estimated 63 to confirmed 62
    • Primary completion date changed from estimate of Dec 31, 2025 to Sep 2, 2025
    • Study completion date: Dec 31, 2025 to Jan 19, 2027
    v61
  4. Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography (Procedure), Magnetic Resonance… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Echocardiography Test (Procedure)…v57
  5. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 6 of 6 sites
    v49
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v48
  2. Notable Eligibility criteria expanded, about 50 wordsv46
  3. Notable Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v45
  4. Minor Site details revised at 2 of 6 sitesv44
  5. Minor Site details revised at 1 of 6 sitesv43
  6. Minor Site details revised at 1 of 6 sitesv42
  7. Minor Site details revised at 1 of 6 sitesv39
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Total Topoisomerase 1 (TOP1) Levels in Biopsy Specimens at Early and Late Post-Trastuzumab Deruxtecan (DS-8201a) Time Points
Timeframe: (Early post treatment compared to baseline) - Up to day 7 of cycle 1 (one cycle = 21 days), for an average of 3.2 days; (late post treatment compared to baseline) Day 1 of cycle 3, for an average of 47 days
Tumor Immune Microenvironment Response After Trastuzumab Deruxtecan (DS-8201a) Treatment
Timeframe: Baseline compared to Day 1 of cycle 3 (1 cycle = 21 days), for an average of 47 days

Secondary (5)

Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Concentration and Change in Total TOP1 Levels in Tumor Biopsies
Correlation Between Maximum Serum Concentration of Trastuzumab Deruxtecan (DS-8201a) and the Initial Change in TOP1cc in Tumor Biopsies (From Baseline to Cycle 1, 2-4 Days Post-day 1 Dose)
Correlation Between Participants' Trastuzumab Deruxtecan (DS-8201a) Serum Area Under the Curve (AUC) Calculation and Change in Total TOP1 Levels in Tumor Biopsies
Number of Participants With Grade 2 and Higher Treatment-related Adverse Events, Reporting Only the Worst Grade That is at Least Possibly Related to Study Drugs for Each Participant
Overall Response Rate

Arms and interventions

Treatment (trastuzumab deruxtecan)Experimental

Patients receive trastuzumab deruxtecan intravenous (IV) over 30-90 minutes on day 1 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiogram (ECHO) or multi-gated acquisition scan (MUGA), computed tomography (CT) or magnetic resonance imaging (MRI), biopsies, and collection of blood samples throughout the study.

Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan

Biologicals: Trastuzumab Deruxtecan

Sites

6 sites in 1 country